Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 14, 2018

SELL
$60.72 - $167.34 $687,289 - $1.89 Million
-11,319 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $694,986 - $1 Million
11,319
11,319 $705,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Harbourvest Partners LLC Portfolio

Follow Harbourvest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbourvest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Harbourvest Partners LLC with notifications on news.